Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. South Africa
  4. Johannesburg Stock Exchange
  5. Aspen Pharmacare Holdings Limited
  6. News
  7. Summary
    APN   ZAE000066692

ASPEN PHARMACARE HOLDINGS LIMITED

(APN)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ASPEN CONFIRMS NON-BINDING TERM SHEET ON MANUFACTURE AND SALE OF AN ASPEN BRANDED COVID-19 VACCINE THROUGHOUT AFRICA

12/01/2021 | 09:57am EST

Durban, South Africa - JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, is pleased to confirm that one of its wholly-owned South African subsidiaries, Aspen SA Operations (Pty) Limited ('Aspen SA'), has confirmed a non-binding term sheet with Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica NV, two of the Janssen Pharmaceutical Companies of Johnson & Johnson ('Johnson & Johnson'), that will form the basis for negotiation of a definitive agreement on the manufacture and sale of an Aspen-branded COVID-19 vaccine throughout Africa.

That agreement would expand the existing technical transfer and manufacturing agreements between the parties to grant Aspen SA the rights to: manufacture finished SARS-CoV-2 COVID-19 vaccine product from COVID-19 drug substance supplied by Johnson & Johnson; and sell the finished form vaccine, to be launched and branded as Aspenovax, to public sector markets in Africa through transactions with designated multilateral organisations and with national governments of member states of the African Union.

In addition, Johnson & Johnson would grant Aspen a license to the enabling intellectual property for this purpose.

The term of the grant of rights and supply of COVID-19 drug substance, subject to the signing of the definitive agreement, would be until 31 December 2026. The non-binding term sheet contemplates a good faith undertaking between the parties to discuss the expansion of the agreement to include any new versions of the drug substance, such as those developed for new variants or as a different formulation for administration as a booster, and the applicable terms thereof.

Stephen Saad, Aspen Group Chief Executive said, 'The COVID-19 pandemic has highlighted the inequitable access to vaccines globally. This is evident no more so than in Africa which has historically had no option but to import 99% of its vaccine requirements. Those regions with manufacturing capacity and capabilities have enjoyed ready access to COVID-vaccines, those without have not. Africa remains vaccine constrained, preventing an effective response to the need to protect Africans against the virus. We are most grateful to Johnson & Johnson for their confidence in collaborating with Aspen to address these challenges.'

'Through our contract manufacturing partnership with Johnson & Johnson, Aspen has been able to manufacture over 100 million doses of the Janssen COVID-vaccine to date, almost all of which have been supplied to Africa, and today, we are pleased to share the progress being made that would enable Aspen the rights to manufacture and sell Aspen's own brand of the vaccine in Africa. This has the potential to represent a bold step forward in sustainably capacitating Africa with the ability to manufacture Aspenovax and release it exclusively for supply to African customers. A COVID-19 vaccine made in Africa for Africa.'

Stephen Saad added, 'As with the solution found over a decade ago resulting in voluntary licenses for antiretrovirals used in treating HIV/AIDS, we hope that this potential license agreement and related technical transfers might serve as a blue-print to assist in capacitating Africa and other developing markets and in so doing ensure that we can truly live and give substance to our global commitment that we are not safe until we are all safe.'

President Cyril Ramaphosa, African Union COVID champion said, 'The effectiveness of our response as the African continent to the COVID-19 pandemic has been severely hampered by the grossly unequal distribution of COVID vaccines across the world. Today's landmark announcement between Africa'sAspen Pharmacare and Johnson & Johnson is the culmination of months of hard work with, among others, the African Union, Africa Centres for Disease Control and Prevention and the African Vaccine Acquisition Trust, in developing production capacity on the continent. This announcement has the potential to make an important contribution to addressing vaccine inequality and building Africa's capacity to meet its own vaccine needs now and into the future.'

Strive Masiyiwa, African Union special envoy on COVID and Head of the AVAT Trust, said 'The biggest and boldest step that Africa took through the Africa Vaccine Acquisition Trust and African Union, was signing a contract with Johnson & Johnson for 400 million doses for the continent, the majority to be produced by Aspen. Today's announcement is an important milestone. It gets us one step closer to securing Africa's future vaccine production and ensures that the gross vaccine inequality we witnessed in the early part of the pandemic is not repeated.'

'We welcome this agreement. It is a major development which will help reduce the inequities Africa is facing in accessing COVID-19 vaccines. This cooperation and technology transfer arrangement is an important step forward towards increasing Africa's manufacturing capacity and the push to ramp up access to vaccines and other key medical interventions,' said Dr Matshidiso Moeti, World Health Organization Regional Director for Africa.

Contact:

Aspen Holdings Head Office

Durban, South Africa

Aspen Place

9 Rydall Vale Park

Douglas Saunders Drive

La Lucia Ridge

Tel: +27 31 580-8600

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about ASPEN PHARMACARE HOLDINGS LIMITED
10:10aASPEN PHARMACARE : Business update for the six months ended 31 December 2021 and withdrawa..
PU
2021ASPEN PHARMACARE HOLDINGS LIMITED : Proxy Statments
CO
2021ASPEN PHARMACARE : Report on Annual General Meeting proceedings
PU
2021Africans Will Get Wider Access to Vaccines in New Distribution Deal
AQ
2021Aspen confirms non-binding term sheet on manufacture and sale of an aspen branded covid..
AQ
2021S.Africa's Aspen signs deal paving way for J&J COVID vaccine licence
RE
2021South Africa's rand finds support in weaker dollar, stocks firm
RE
2021African Union calls for Aspen-J&J deal to include substance production
RE
2021Johnson & Johnson Units, Aspen Pharmacare Sign Term Sheet for Manufacturing of COVID-19..
MT
2021ASPEN PHARMACARE : confirms non-binding term sheet on manufacture and sale of an - branded..
PU
More news
Financials
Sales 2022 42 165 M 2 721 M 2 721 M
Net income 2022 7 057 M 455 M 455 M
Net Debt 2022 11 146 M 719 M 719 M
P/E ratio 2022 14,0x
Yield 2022 1,41%
Capitalization 98 966 M 6 387 M 6 386 M
EV / Sales 2022 2,61x
EV / Sales 2023 2,43x
Nbr of Employees 8 844
Free-Float -
Chart ASPEN PHARMACARE HOLDINGS LIMITED
Duration : Period :
Aspen Pharmacare Holdings Limited Technical Analysis Chart | APN | ZAE000066692 | MarketScreener
Technical analysis trends ASPEN PHARMACARE HOLDINGS LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 217,43 ZAR
Average target price 269,40 ZAR
Spread / Average Target 23,9%
EPS Revisions
Managers and Directors
Stephen Bradley Saad Group Chief Executive Officer & Executive Director
Sean Matthew Capazorio Group Finance Officer & Executive Director
Kuseni Douglas Dlamini Chairman
Lorraine Angela Hill Group Operating Officer
Babalwa Ngonyama Independent Non-Executive Director